eligibility_summary
Eligibility: Adults (≥18) with measurable R/R DLBCL/HGBCL or transformed indolent lymphoma after ≥1 line (incl. post–CAR‑T cohort, prior polatuzumab allowed), ECOG ≤2, life expectancy ≥12 wks, adequate counts/organ function, controlled HIV/HBV/HCV, treated brain mets ok, contraception/consent required. Exclude: PMBCL/gray zone/plasmablastic, unresolved ≥G2 tox, active infection or CNS lymphoma, pregnancy/breastfeeding, NYHA >II, >G1 neuropathy, chronic active EBV, solid organ transplant, HLH/PML, uncontrolled autoimmune disease.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 1 single-arm study in relapsed/refractory DLBCL testing three agents: 1) Mosunetuzumab: CD20×CD3 bispecific monoclonal antibody (T‑cell engager) that binds CD20 on B cells and CD3 on T cells to redirect cytotoxic T‑cell killing. 2) Polatuzumab vedotin: anti‑CD79b antibody–drug conjugate delivering vedotin (MMAE), a microtubule inhibitor that induces apoptosis in CD79b+ B cells. 3) Lenalidomide: oral immunomodulatory drug (IMiD) that binds cereblon, drives IKZF1/3 degradation, enhances T/NK-cell function, modulates cytokines, and is anti‑angiogenic. Targets/pathways: malignant CD20+/CD79b+ B cells, B‑cell receptor component CD79b, T‑cell CD3 activation, cereblon/IKZF1/3 axis, microtubule polymerization. Aim: define safety/dose and preliminary activity, including in prior Pola‑ or CAR‑T–treated patients.